Medicare's new GLP-1 Bridge program, launched Wednesday, offers a selection of brand-name weight loss drugs for a $50 monthly copay, but this temporary measure primarily funnels public funds to pharmaceutical giants Eli Lilly and Novo Nordisk, whose medications typically cost hundreds of dollars each month. The program, set to run until the end of 2027, marks the first opportunity for many older adults to secure insurance coverage for these high-cost drugs when used strictly for weight loss.
The "sheer cost" of these medications has been a "huge barrier to access," according to Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services (CMS). He stated he hopes the program will provide "immediate relief to cash-strapped older Americans." However, the $50 monthly payment does not count toward deductibles or out-of-pocket maximums, meaning beneficiaries still face the full burden of other medical expenses while Medicare directly subsidizes the drug corporations.
Eli Lilly’s Foundayo tablets and Zepbound KwikPens, alongside Novo Nordisk’s Wegovy injections and tablets, are among the covered medications. These are the same drugs that have soared in popularity, often costing hundreds of dollars a month for higher doses. The Bridge program ensures a steady stream of revenue for these corporations, paid for by public funds, rather than challenging their exorbitant pricing structures.
Who Profits from the 'Bridge'?
The program's structure effectively transfers public money to private pharmaceutical companies. Medicare, not the Part D insurer, subsidizes the prescription cost. This arrangement bypasses the usual mechanisms that might pressure insurers to negotiate lower prices, instead guaranteeing a market for high-priced drugs. Dr. Oz noted that "other negotiations with drug companies to lower costs are ongoing," yet the Bridge program proceeds with current pricing.
Limited Access, Lingering Barriers
Despite the stated goal of relief, access remains severely restricted. To qualify, beneficiaries must have Medicare drug coverage and a body mass index of 35 or higher, or a BMI of 27 or higher coupled with another specific health condition. People already covered for conditions like diabetes or sleep apnea are explicitly excluded from this program, even if they need the drugs for weight loss. Juliette Cubanski, vice president and director of the program on Medicare policy at KFF, a healthcare research nonprofit, estimates that only a "narrower slice" of the more than 10 million overweight or obese Medicare enrollees will actually gain access.
Katie Smith, a 71-year-old from Virginia, exemplifies these barriers. With a BMI of 33, she isn't sure she meets the additional health condition requirements. Smith, whose mobility was severely limited by a spinal cord injury in her 20s, was previously quoted $700 a month for the medications, a price she couldn't afford. "I cannot tell you how frustrated I am," she told the Associated Press, highlighting how structural barriers prevent even highly motivated individuals from accessing necessary care. Gloria Dralla, 78, from California, who lost 40 pounds buying lower-cost Wegovy in Europe, emphasized that the drug "should be made available at a reasonable price for everybody who’s got weight loss problems."
The State's Role in Corporate Welfare
The federal government's approach to drug access reveals its primary function: managing the system's contradictions while preserving corporate profits. The Bridge program is temporary, scheduled to sunset after December 31, 2027. Congress has not authorized Medicare to cover weight loss drugs permanently, limiting federal options for sustained access. CMS indefinitely delayed another voluntary pilot program called BALANCE earlier this year because many Part D insurers were "reluctant to sign up." This reluctance underscores how private capital dictates the terms of public health initiatives. Dr. Oz stated that a federal law for permanent coverage is "not essential right now," preferring to "carefully track participation and outcomes" before committing to a long-term solution. This deferral ensures that pharmaceutical companies continue to extract maximum surplus value from their products, while the state offers only temporary, conditional relief.